Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

Inclusion Criteria: * Age \>= 18 years of age * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Patients with verified and operable KRAS-positive mutant lung adenocarcinoma, colorectal, or pancreatic cancer * Have available diagnostic, pre-treatment archival tumor tissue * Medically fit for surgical resection * Absolute neutrophil count (ANC) \>= 1500/ uL * Hemoglobin (Hgb) \>= 9 g/dL * Platelet count \>= 100,000/uL * Total bilirubin =\< 1.5 x ULN (upper limit of normal) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2 x ULN * Creatinine clearance \> 60 mL/min (Cockcroft-Gault Equation) * Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria present * Ability to swallow and retain oral medication * Female participants of childbearing potential must agree to use methods of contraception that are highly effective or acceptable, and to not donate ova from screening until 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately * Male participants must agree to use methods of contraception that are highly effective or acceptable, and to not donate sperm from screening until 90 days after the last dose of study drug * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Instit…